Huaier granules for idiopathic membranous nephropathy with PLA2R
Treatments studied
Part of Immune system & allergy, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial studies whether Huaier granules can improve kidney disease activity in people with “idiopathic membranous nephropathy” who test positive for PLA2R antibodies and are still not in remission. Participants will also have been on standard blood-pressure/kidney-protecting treatment (called RASI) for at least 4 weeks.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your kidney biopsy was done before joining and showed idiopathic membranous nephropathy
- Your blood test shows PLA2R antibody is positive
- You are 18 to 75 years old, and either sex
- You have protein in your urine between 3.5 and under 8.0 grams in 24 hours, and it has not fully remitted
- Your kidney filtering function (eGFR) is at least 45 (checked at least twice in 2 weeks)
- You can take stable RASI treatment for at least 4 weeks before joining and agree to sign consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This phase 3 trial tests an experimental drug (HRS-5965) for people with IgA nephropathy (a kidney disease). It aims to find out if the drug can help reduce protein in the urine and protect kidney function. To join, you must have had a kidney biopsy showing IgA nephropathy within the past 8 years and have significant protein in your urine despite taking standard treatments.
This trial tests a new medicine called HS-10542 for people with IgA nephropathy, a kidney disease. It aims to see if the drug is safe and helps reduce protein in the urine, which is a sign of kidney damage.
This trial tests a combination of two medications, rituximab and cyclosporine, for people with primary membranous nephropathy, a kidney disease that causes protein in the urine. The goal is to see if this combination can reduce protein loss and improve kidney function, potentially preserving kidney health.
This trial tests a new drug called HLX79 (a human sialidase fusion protein) combined with rituximab, compared to a placebo, for people with active membranous nephropathy (a kidney disease). It aims to see if this combination can reduce protein in the urine and improve kidney function.
This trial tests a new medicine called HS-10390 to see if it can help people with IgA nephropathy, a kidney disease. It aims to reduce protein in the urine and protect kidney function.
This study tests whether Huaier granules, a Chinese herbal medicine, can reduce protein in the urine caused by bevacizumab or anlotinib treatment for lung cancer. If you're experiencing this side effect, the trial may help manage it.
Hear when a new Nephropathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.